BEIJING, Oct. 13, 2011 /PRNewswire-Asia-FirstCall/ --
China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a
leading China-based advanced
in-vitro diagnostic ("IVD") company, today announced that
China's State Food and Drug
Administration (the "SFDA") has approved the Company's real-time
PCR-based V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
("KRAS") assay (the "PCR KRAS Assay") as a companion diagnostic
test for the use of a targeted drug for the treatment of colorectal
cancer patients.
The PCR KRAS Assay is a diagnostic assay used for the detection
of specific mutations in the KRAS gene using a real-time PCR
analyzer. It predicts which colorectal cancer patients are likely
to respond to and benefit from the targeted drug. About 60% of
colorectal cancer patients have a non-mutated KRAS gene, while the
remaining colorectal cancer patients with mutations may not be
responsive to the targeted drug.
According to the Chinese Ministry of Health, colorectal cancer
is one of the most common digestive tract cancers. About 170,000
new colorectal cancer cases were diagnosed each year in
China, and the incidence rate is
expected to increase.
The PCR KRAS Assay expands the Company's SFDA approved product
portfolio of companion diagnostic tests for targeted cancer drugs.
The product portfolio currently includes FISH HER-2 kit for breast
cancer targeted drug and stomach cancer targeted drug, FISH BCR/ABL
kit for leukemia targeted drug, FISH EGFR kit and PCR EGFR assay
for non-small cell lung cancer targeted drug as well as the newly
approved PCR KRAS assay for colorectal cancer targeted drug. The
Company plans to continue focusing on expanding its product
portfolio.
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using
molecular diagnostic technologies including Fluorescent in situ
Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an
immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay
(ECLIA), to develop, manufacture and distribute diagnostic products
used for the detection of various cancers, diseases and disorders
as well as companion diagnostic tests for targeted cancer drugs.
The Company generates all of its revenues in China through the sale of diagnostic
consumables including FISH probes, SPR-based DNA chips and ECLIA
reagent kits to hospitals which are recurring users of the
consumables for their patients. The Company sells FISH probes and
SPR chips to large hospitals through its direct sales force and
ECLIA reagent kits to small and mid-size hospitals through
distributors. For more information, please visit
http://www.chinameditech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar
statements. Such statements involve certain risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Further information regarding these
and other risks is included in the Company's filings with the U.S.
Securities and Exchange Commission, including its annual report on
Form 20-F. The Company does not undertake any obligation to update
any forward-looking statement as a result of new information,
future events or otherwise, except as required under applicable
law.
|
Contact
|
|
|
|
|
Winnie Yam
|
|
|
Tel: 852-2511-9808
|
|
|
Email: IR@chinameditech.com
|
|
|
SOURCE China Medical Technologies, Inc.